Biogen-Backed Stoke Therapeutics Reports Promising Dravet Syndrome Data in NEJM
Event summary
- Phase 1/2a and open-label extension studies of zorevunersen showed substantial and durable reductions in seizures and improvements in cognition and behavior for Dravet syndrome patients.
- The NEJM publication supports the ongoing global Phase 3 EMPEROR study, with data readout expected in mid-2027.
- Zorevunersen has been generally well tolerated, with 81 patients receiving at least one dose and over 800 doses administered across studies.
- Stoke Therapeutics and Biogen have a strategic collaboration for the development and commercialization of zorevunersen, with Biogen holding exclusive rights outside the U.S., Canada, and Mexico.
The big picture
The publication in NEJM marks a significant milestone in the treatment of Dravet syndrome, a rare and devastating genetic neurodevelopmental disease. The data suggest that zorevunersen, an investigational antisense oligonucleotide, could be the first disease-modifying therapy for the condition. This development comes as the biotechnology and pharmaceutical industries increasingly focus on RNA medicine and targeted therapies for rare diseases. The strategic collaboration between Stoke Therapeutics and Biogen underscores the growing emphasis on partnerships to accelerate the development of innovative treatments.
What we're watching
- Clinical Validation
- Whether the Phase 3 EMPEROR study results will confirm the disease-modifying potential of zorevunersen and support regulatory approval.
- Commercial Strategy
- How Biogen and Stoke Therapeutics will position zorevunersen in the rare disease market, given the lack of approved disease-modifying therapies for Dravet syndrome.
- Execution Risk
- The pace at which Stoke Therapeutics and Biogen can advance zorevunersen through regulatory pathways and bring it to market, considering the complexity of Dravet syndrome treatment.
Related topics